Observational studyRevista medica del Instituto Mexicano del Seguro Social2024
[Survival after hematopoietic stem cell transplantation with identical and haploidentical donors].
Observational study in Revista medica del Instituto Mexicano del Seguro Social, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a therapy that offers the potential to cure hematological malignancies. One limitation is that only 25% of patients will have an identical donor. The use of haploidentical donors allows 95% of patients to have a donor. Experience in Mexico with haploidentical HSCT is limited. In 2018, the Haploidentical Transplantation Program began at the Hospital de Especialidades (Specialties Hospital) from the Centro Médico Nacional Siglo XXI (21st Century National Medical Center). Objective: To compare the overall survival of patients undergoing HSCT with an identical or haploidentical donor at the Hospital de Especialidades. Material and methods: A retrospective, observational study was carried out in patients undergoing HSCT at the Hospital de Especialidades, from January 2018 to December 2022. All patients who received HSCT were included. Overall survival analysis was performed using Kaplan-Meier curves. A significance level of p < 0.05 was considered. Results: 109 patients who underwent to allogeneic HSCT were analyzed, 34% of them had a haploidentical donor. There were no differences in overall survival. The haploidentical group presented greater cytomegalovirus reactivation and less chronic graft-versus-host disease (GVHD). Conclusions: No differences in survival were found in both groups, which is why haploidentical transplantation could be a good treatment option in patients who do not have an identical donor at our institution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.